TABLE 2.

Patient's response according to RECIST v1.1 in FAS

Best overall response, n (%)	Sintilimab arm (n = 145)	Docetaxel arm (n = 135)
CR	1 (0.7)	0
PR	36 (24.8)	3 (2.2)
SD	58 (40.0)	48 (35.6)
PD	39 (26.9)	48 (35.6)
NE	11 (7.6)	36 (26.7)

RECIST: Response Evaluation Criteria in Solid Tumors; v1.1: version 1.1; FAS, full analysis set; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluable according to RECIST v1.1 criteria; CI: confidence interval.